ArticleWorld journal of urology2022

Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.

Shintaro Narita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.